Monte Book Value Per Share from 2010 to 2024

GLUE Stock  USD 4.01  0.15  3.61%   
Monte Rosa's Book Value Per Share is increasing over the years with slightly volatile fluctuation. Book Value Per Share is expected to dwindle to 2.45. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Monte Rosa Therapeutics according to its financial statements. View All Fundamentals
 
Book Value Per Share  
First Reported
2010-12-31
Previous Quarter
3.48756029
Current Value
2.45
Quarterly Volatility
2.58255073
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Monte Rosa financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Monte Rosa's main balance sheet or income statement drivers, such as Net Interest Income of 9.4 M, Depreciation And Amortization of 6.5 M or Interest Expense of 4.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.7. Monte financial statements analysis is a perfect complement when working with Monte Rosa Valuation or Volatility modules.
  
Check out the analysis of Monte Rosa Correlation against competitors.

Latest Monte Rosa's Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Monte Rosa Therapeutics over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Monte Rosa's Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Monte Rosa's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 3.04 X10 Years Trend
Slightly volatile
   Book Value Per Share   
       Timeline  

Monte Book Value Per Share Regression Statistics

Arithmetic Mean1.02
Coefficient Of Variation253.46
Mean Deviation2.01
Median(0.28)
Standard Deviation2.58
Sample Variance6.67
Range8.5751
R-Value0.62
Mean Square Error4.42
R-Squared0.38
Significance0.01
Slope0.36
Total Sum of Squares93.37

Monte Book Value Per Share History

2024 2.45
2023 3.49
2022 5.75
2021 7.47
2020 -1.11

Other Fundumenentals of Monte Rosa Therapeutics

Monte Rosa Book Value Per Share component correlations

0.970.97-0.69-0.830.840.80.550.97-0.450.99-0.850.990.87-0.850.860.65-0.45
0.970.95-0.78-0.720.70.870.341.0-0.360.98-0.740.990.77-0.740.760.51-0.36
0.970.95-0.71-0.890.820.670.510.95-0.630.96-0.790.950.79-0.790.90.72-0.63
-0.69-0.78-0.710.36-0.38-0.650.01-0.780.2-0.760.49-0.79-0.510.49-0.36-0.180.2
-0.83-0.72-0.890.36-0.92-0.35-0.78-0.720.82-0.790.8-0.74-0.770.8-0.99-0.930.82
0.840.70.82-0.38-0.920.420.90.7-0.610.81-0.920.750.93-0.920.90.85-0.61
0.80.870.67-0.65-0.350.420.090.870.090.82-0.570.850.62-0.570.450.090.09
0.550.340.510.01-0.780.90.090.34-0.560.48-0.790.410.78-0.790.750.81-0.56
0.971.00.95-0.78-0.720.70.870.34-0.350.98-0.740.990.76-0.740.760.5-0.35
-0.45-0.36-0.630.20.82-0.610.09-0.56-0.35-0.420.52-0.39-0.430.52-0.77-0.791.0
0.990.980.96-0.76-0.790.810.820.480.98-0.42-0.841.00.86-0.840.820.58-0.42
-0.85-0.74-0.790.490.8-0.92-0.57-0.79-0.740.52-0.84-0.8-0.991.0-0.81-0.620.52
0.990.990.95-0.79-0.740.750.850.410.99-0.391.0-0.80.82-0.80.780.53-0.39
0.870.770.79-0.51-0.770.930.620.780.76-0.430.86-0.990.82-0.990.790.6-0.43
-0.85-0.74-0.790.490.8-0.92-0.57-0.79-0.740.52-0.841.0-0.8-0.99-0.81-0.620.52
0.860.760.9-0.36-0.990.90.450.750.76-0.770.82-0.810.780.79-0.810.89-0.77
0.650.510.72-0.18-0.930.850.090.810.5-0.790.58-0.620.530.6-0.620.89-0.79
-0.45-0.36-0.630.20.82-0.610.09-0.56-0.351.0-0.420.52-0.39-0.430.52-0.77-0.79
Click cells to compare fundamentals

About Monte Rosa Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Monte Rosa income statement, its balance sheet, and the statement of cash flows. Monte Rosa investors use historical funamental indicators, such as Monte Rosa's Book Value Per Share, to determine how well the company is positioned to perform in the future. Although Monte Rosa investors may use each financial statement separately, they are all related. The changes in Monte Rosa's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Monte Rosa's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Monte Rosa Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Monte Rosa. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Book Value Per Share 3.49  2.45 
Tangible Book Value Per Share 3.49  2.45 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Monte Stock

When determining whether Monte Rosa Therapeutics is a strong investment it is important to analyze Monte Rosa's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monte Rosa's future performance. For an informed investment choice regarding Monte Stock, refer to the following important reports:
Check out the analysis of Monte Rosa Correlation against competitors.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.51)
Revenue Per Share
0.02
Return On Assets
(0.31)
Return On Equity
(0.68)
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.